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Patients entered the model according to three different adhesion states related 
to each treatment drug - fully compliant, partially compliant and non-compliant 
– and could subsequently transition between different health states during each 
monthly cycle. Probability of relapse, level of adherence, treatment discontinuation 
and adverse events associated with each intervention were sourced from literature 
and while resource use was obtained from specialist’s opinion. Costs and outcomes 
were evaluated over a 5-year horizon, and discounted at 5.0%. Exchange rate (1 
USD = 2.30 BRL) Results were presented as incremental costs/relapses avoided. 
Deterministic and probabilistic sensitivity analyses were performed Results: Total 
costs (USD): PP (15,917), OP (13,670), QP (16,845) and ZP (13,273). Hospitalization 
relapses costs (USD): PP (3,114), OP (4,504), QP (6,305) and ZP (6,459). Relapses rate: PP 
(1.15), OP (1.67), QP (2.37) and ZP (2.41). Incremental cost per relapses avoided (USD/
relapses avoided): PP vs. OP (2,247), PP vs. QP (-927), PP vs. ZP (2,644). ConClusions: 
Compared with the drugs under analysis, PP demonstrates savings in terms of 
hospitalization costs. Additionally, PP is a cost-saving strategy compared to QP and 
when compared to OP and ZP, is a cost-effective therapy for the treatment of schizo-
phrenia in adults patients in Brazil.
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objeCtives: Effective therapy with different drug formulations exists for Attention 
Deficit Hyperactivity Disorder (ADHD), yet poor adherence leads to suboptimal 
long-term effects for children and adolescents with ADHD. This study analyzes 
the cost-effectiveness of medication formulation (long-acting [LA] versus short-
acting [SA]) for ADHD treatments in children and adolescents taking into account 
medication adherence. Methods: We constructed a hybrid decision tree-Markov 
model employing a third-party payer’s perspective. Evaluation included methyl-
phenidate (MPH) and atomoxetine (ATX) with long- and short-acting formulations, 
which resulted in three medication groups for comparison: LA-ATX, LA-MPH, and 
SA-MPH. Only medication costs for ADHD treatments are considered, which were 
retrieved from Consumer Reports Best Buy DrugsTM report. Quality-adjusted life expec-
tancy (QALE) was measured in quality-adjusted life-years (QALYs) considering side 
effects among medication groups. The 5-year discounted incremental costs (in 
2013 US dollars) per QALY (ICER) were reported comparing the three medication 
groups. Sensitivity analyses were performed to test the impact of uncertain model 
parameters on results. Results: Considering medication adherence, the ICERs are 
$18,926/QALY for LA-ATX ($3,417, 4.33 QALYs), $11,335/QALY for LA-MPH ($1,288, 4.26 
QALYs), and $7,816/QALY for SA-MPH ($591, 4.23 QALYs), respectively, compared 
to no treatment. LA medications are consistently cost-effectiveness compared to 
SA medications. In general, the ICERs were insensitive to variation in key param-
eters. ConClusions: LA-ATX, LA-MPH, and SA-MPH are cost-effective alternatives 
for children and adolescents with ADHD when considering medication adherence. 
Treatment with long-acting medications, especially ATX, is associated with better 
health outcomes and higher medication adherence. Given there is little difference 
in health outcomes among the therapies; however, additional research on optimal 
ADHD treatments (pharmacological, behavioral, or combined therapies) is needed.
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bACkgRound/objeCtives: Risperidone is a commonly used antipsychotic for 
the treatment of schizophrenia. Its major metabolic pathway is through the liver 
enzyme CYP2D6. Variants of CYP2D6 confer differing activity levels. Poor metabo-
lizer phenotype is suspected to increase the risk of adverse drug reactions that 
could lead to risperidone discontinuation and poor patient outcomes. The objective 
of this study was to assess the potential costs and outcomes of a pharmacogenetic-
guided risperidone treatment strategy for use in schizophrenics. Methods: A 
decision analytic model was developed to estimate the incremental cost per QALY 
gained (ICER) and cost per relapse and hospitalization avoided, associated with 
a pharmacogenetic-guided strategy compared to a standard treatment approach 
for a hypothetical schizophrenic patient initiated on risperidone. We used a one-
year time horizon and a payer perspective. Model probabilities, costs, and utilities 
were obtained from the literature. One-way sensitivity analyses were performed 
to explore the possible range of results. Results: For one patient entering the 
model, pharmacogenetic-guided treatment increased QALYs (0.00047), and pre-
vented relapses (0.00782) as well as relapse-associated hospitalizations (0.00235) 
at an increased total cost ($167). This resulted in an ICER of $356,356, and costs 
of $21,468 per relapse avoided and $71,561 per hospitalization avoided relative to 
standard treatment. Findings were robust to one-way sensitivity analyses and did 
not change the base case Conclusions. ConClusions: Our results suggest a phar-
macogenetic-guided treatment approach for risperidone may confer a small reduc-
tion in relapses and consequent hospitalizations, and a very minimal increase in 
QALYs for relatively low additional cost compared to standard treatment. However, 
the large ICER suggests this approach is not cost effective.
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than the other two strategies. Compared to clonidine/guanfacine, AAPs provided a 
lower QALY (0.11 QALY lost) at an additional cost of $2,186 on average. Compared to 
atomoxetine, AAPs resulted in 0.10 QALY lost at an additional cost of $2,186. These 
results were robust in sensitivity analyses. ConClusions: In this decision analysis 
model, AAPs provide lower expected health outcomes than other ADHD medications 
(atomoxetine, clonidine, or guanfacine) in children and adolescents who failed prior 
stimulant therapy. Furthermore, AAPs were not a cost-effective option.
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objeCtives: Staying in structured drug treatment for more than 12 weeks is 
a strong predictor of positive outcomes. Higher doses of buprenorphine and 
buprenorphine-naloxone appear to be more effective for retaining clients in treat-
ment, though the incremental cost per retained client associated with each dose is 
unknown. This study estimated cost-effectiveness thresholds for prescribing higher 
doses of buprenorphine/buprenorphine-naloxone to retain individuals in treatment 
for at least 12 weeks. Methods: Dose, treatment duration, and retention data 
were extracted or computed from 14 randomised, controlled, double-blind clinical, 
12-26 week trials of buprenorphine/buprenorphine-naloxone maintenance treat-
ment of opioid-dependent individuals (N = 1,897). Treatment costs included drug 
preparations and supervised consumption of doses. Retention in treatment was 
used as the primary measure of clinical effectiveness. Results: Weighted mean 
treatment retention rates were 49% (2 to 7.9-mg/day), 53% (8 to 15.9-mg/day), 60% 
(16 to 23.9-mg/day) and 58% (24 to 32-mg/day). Controlling for differences in treat-
ment duration, patients dosed with 16 to 23.9-mg/day, 24 to 32-mg/day, and 8 to 
15.9-mg/day were 47% (p = 0.001), 37% (p = 0.275), and 8% (p = 0.498) more likely to 
stay in treatment for 12-26 weeks compared to patients dosed with 2 to 7.9-mg/day. 
Compared to 8 to 15.9-mg/day, a 16 to 23.9-mg/day dose was estimated to yield an 
additional 65 retentions per 1000 patients treated at an additional cost of £74,968 
(incremental cost per retention = £1,158). ConClusions: If UK decision makers’ 
willingness-to-pay to retain one patient in treatment for at least 12 weeks is greater 
than £1,158, then buprenorphine/buprenorphine-naloxone prescribed at a dose of 
16 to 23.9-mg/day may cost-effectively increase the treatment retention rate.
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objeCtives: The risks of smoking during pregnancy are numerous to both mother 
and fetus. While the negative effects of smoking during pregnancy can be long-
term, medical costs that are most easily linked to smoking during pregnancy occur 
shortly following birth. For example, smoking during pregnancy often results in 
prolonged hospitalization and admission of the infant to a neonatal intensive care 
unit (NICU), at a cost of thousands of dollars daily. We set out to perform the first 
health economic analysis of incentive-based treatments in a smoking, pregnant 
population. Methods: The design of the present study was based on analysis of 
recent prospective studies examining the use of contingency management (CM) for 
the treatment of smoking during pregnancy. The resultant pooled analysis totaled 
166 women (82 contingent, 78 non-contingent) for whom clinical outcomes and 
direct hospital costs were reported. Pregnant women who reported smoking upon 
entering prenatal care were recruited from Fletcher Allen Health Care obstetric 
practices and Women, Infants, and Children (WIC) offices in and around Burlington, 
Vermont. Women were randomized between two conditions: contingent or noncon-
tingent vouchers. Those in the contingent condition received vouchers exchange-
able for retail goods contingent upon cotinine-negative urine analysis. Women in the 
non-contingent condition received vouchers independent of their smoking status. 
Vouchers were provided throughout pregnancy and for the first 3 months postpar-
tum. Results: As compared with non-contingent care, CM led to a nearly 3-fold 
reduction in admissions to the neonatal intensive care unit (NICU). Only 7.0% of 
CM women delivered infants admitted to the NICU (median charge = $9,210) versus 
19.2% among non-contingent women (median charge = $11,363). The findings from 
this study suggest that these cash-like incentives targeting at-risk patients are 
not only cost-effective but also cost-saving in pregnant smokers. ConClusions: 
Incentive-based treatment towards smoking abstinence dominated usual care with 
both better outcomes and lower economic costs.
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objeCtives: Schizophrenia is a chronic disorder that requires long-term treatment 
with antipsychotic medication to minimize relapse and provide benefit to patients. 
Due to the long duration of treatment, adherence is an important factor in order to 
avoid relapses and re-hospitalization. Long-acting Injectable (LAI) formulations of 
atypical antipsychotics provide constant medication delivery and thus a potential 
improve in adherence. The aim of this analysis is to assess the cost-effectiveness of 
paliperidone palmitate (PP) relative to olanzapine (OP), quetiapine (QP) and ziprazi-
done (ZP) under the Brazilian Private Healthcare System perspective. Methods: A 
decision-analytic Markov model was developed adopting a monthly cycle length. 
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objeCtives: To develop an economic model that estimates the cost burden of psy-
chiatric relapse and recidivism among patients with schizophrenia after release 
from jail/prison from a US state government perspective. Methods: A Markov 
state-transition model was developed to estimate the numbers of schizophrenia 
patients newly-released from jail/prison who would experience psychiatric relapse 
and/or arrest and re-incarceration over a period of three years, along with corre-
sponding costs. The model includes three health states: 1) in community, on therapy, 
2) in community, off therapy, and 3) incarcerated. A patient’s probability of psychi-
atric hospitalization increases with treatment discontinuation, and the probability 
of arrest increases with the risk of a psychiatric hospitalization. Data from the US 
Census and Bureau of Justice Statistics were used to estimate the model population. 
Published literature was used to estimate the risks of psychiatric relapse, arrest, 
and direct cost inputs associated with hospitalization, arrest, trial, and incarcera-
tion. Felony and misdemeanor incarceration rate and sentence length data from 
the State of Florida were applied as a base case scenario. The rate of antipsychotic 
treatment following release from jail/prison and annual risk of medication dis-
continuation were varied in sensitivity analyses. Results: Among 34,500 persons 
released from Florida state prison annually, 5,307 were estimated to have schizo-
phrenia. The estimated three-year cumulative direct costs to the state government 
were $21,146,000 and $25,616,000 for criminal justice and psychiatric hospitalization 
costs, respectively ($3,985 per patient criminal justice costs; $4,827 per patient hos-
pitalization costs). An absolute 20% increase in the proportion of patients receiving 
antipsychotic treatment following release from jail/prison decreased total cumu-
lative costs over three years by $588 per patient. ConClusions: The economic 
impact of recidivism and psychiatric relapse among patients with schizophrenia is 
substantial from a state government perspective. This general model can be made 
state-specific by utilizing local criminal justice data sources.
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objeCtives: It is not known the profile of the children or the economic and social 
impact of autism in Brazil. The support therapy to children with autism includes 
psychologist, speech therapist, and occupational therapy. Antipsychotics are being 
used in autism treatment. We aimed to know the profile of children with autism and 
the social and economic impact of the disease in their families. Methods: Simple 
Internet survey conducted among Brazilian autism communities during October 
2013. We performed descriptive statistics. All monetary values are in Brazilian reais 
(BRL). Results: We obtained 48 responses. 70.8 % of autism patients were boys. The 
median age was 8 years and 54 % of the patients were between 6 and 10 years. 65 % 
of the diagnoses were made between 2 and 4 years of age. The median number of 
physicians visited to achieve diagnosis was 3, 56% of the children visited 1-3 doctors 
and 23 % had to visit more than 5 doctors. Risperidone was used by 48% of cases 
and main reported side effects were insomnia (10 %), agitation (47 %), anxiety (23 %), 
headache (7 %), and self-reported changes in eating habits (13 %). 28 % of patients 
reported some food allergy. To provide support therapy to children with autism 34 
% of families spend between 500-1500 BRL; 1500 to 2500 (19 %), 2500-3500 (17 %) 
and 2% spend 3500-4500. In 13 % spending was less than 500 and in 15 % spent over 
4500. In 53% of the families the expenditure with support therapy is higher than 
the median household income in Brazil (R$ 1,211.33). ConClusions: Our results 
were in agreement with literature considering gender, age at diagnosis, frequency 
of food allergy and use of antipsychotics. Support therapy for these children can be 
higher than the median household income in Brazil.
Mental HealtH – Patient-reported outcomes & Patient Preference studies
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objeCtives: To assess the impact of baseline characteristics, including prior year 
adherence and use of paliperidone palmitate (PP), on AP continuity metric perfor-
mance. Methods: Medicaid health care claims data from five states (2008-2011) 
were used to identify patients 25-64 years of age diagnosed with schizophrenia and 
≥ 1 AP Rx in baseline year 2010 (BY) and in measurement year 2011 (MY). Adherence 
to AP was defined as the percentage with dispensed AP medication covering ≥ 80% 
of a given year. Baseline year characteristics including demographics, health care 
costs, AP treatment and adherence status were evaluated as potential predictive 
factors of MY continuity using multivariate logistic analyses. Two mutually exclusive 
cohorts (patients with any PP claim vs. all other AP patients in BY) were compared 
on continuity measure performance using inverse propensity score weighting (IPW), 
with propensity representing the likelihood of PP treatment based on BY charac-
teristics. Results: In the study population of 12,990 AP users, 48.6% successfully 
achieved the AP continuity criteria in MY. After controlling for other covariates, the 
likelihood of continuity measure success was improved by adherence in BY (odds 
objeCtives: To examine the economic burden and health care utilizations of 
depression patients in the U.S. veteran population. Methods: Patients diagnosed 
with depression were identified (International Classification of Disease, 9th Revision, 
Clinical Modification [ICD-9-CM] diagnosis codes 296.2x, 296.3x, 300.4, 301.13, 309.0x 
and 311.xx) using the Veterans Health Administration (VHA) Medical SAS datasets 
from October 1, 2007 through September 30, 2012. The initial diagnosis date was 
designated as the index date. A comparison cohort was created for patients with-
out a depression diagnosis, using 1:1 propensity score matching to control for age, 
region, gender, index year and baseline Charlson Comorbidity Index score. For the 
comparison cohort, the index date was randomly chosen to minimize selection bias. 
Patients in both cohorts were required to be at least age 18 years, and have continu-
ous medical and pharmacy benefits 1 year pre- and 1 year post-index date. Study 
outcomes (health care costs, utilizations) were compared between the disease and 
comparator cohorts, based on the matched sample. Results: After 1:1 matching, a 
total of 614,093 patients were identified in each group, and baseline characteristics 
were well-balanced. Patients diagnosed with depression were more likely to have 
inpatient stays (12.73% vs. 2.09%, p< 0.0001) and emergency room (ER) (18.64% vs. 
6.24%, p< 0.0001), physician office (99.59% vs. 54.08%, p< 0.0001), outpatient (99.70% 
vs. 54.83%, p< 0.0001) and pharmacy visits (90.49% vs. 52.20%, p< 0.0001). Higher 
all-cause inpatient stay ($4,017 vs. $599, p< 0.0001), ER visit ($199 vs. $55, p< 0.0001), 
physician office visit ($4,034 vs. $1,152, p< 0.0001), total outpatient ($4,477 vs. $1,304, 
p< 0.0001), pharmacy ($724 vs. $327, p< 0.0001) and total health care costs ($9,218 vs. 
$2,230, p< 0.0001) were also observed for depression patients relative to comparator 
patients. ConClusions: During a period of 12 months, VHA patients diagnosed 
with depression reported higher health care utilization and costs than matched 
control patients.
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objeCtives: To understand key economic risk factors that are associated with the 
following mental health conditions for former regular forces personnel who had 
served with the Canadian army. These health conditions include mood disorders, 
depression, anxiety, post-traumatic stress disorder (PTSD) and combined mental 
health status of all four conditions. Methods: Using different forms of regression 
analysis of cross-sectional data obtained from a survey conducted by Statistics 
Canada in 2010-11 of former army forces personnel. Key risk categories were iden-
tified from economic theory and include educational attainment, military career 
characteristics, behavioural characteristics, income and demographic characteris-
tics. Regression analysis conducted included ordinary-least squared regression, logit 
and probit analysis. In addition, various diagnostic tests were conducted to ensure 
the robustness of econometric models. Results: The results showed that higher-
earning personnel had a significantly lower risk of mental health conditions than 
lower-earning personnel. Obesity significantly increases the risk of mental health 
conditions. Younger former personnel had a significantly greater risk of mental 
health conditions than their older counterparts. Another significant association was 
gender where female personnel showed a greater risk of mental health disorders. 
Deployment for extended periods outside Canada was also shown to be significantly 
associated with increased risk. Rank within the military and the branch of deploy-
ment did not show a significant association with increased risk. The results also 
showed that the higher the educational attainment, the lower the risk of mental 
health conditions though this result was not significant. Significance was set at the 
5% level. ConClusions: This study is the first comprehensive analysis of economic 
risk factors associated with mental health conditions of former army personnel in 
Canada. The results aligned with established economic theory. Additional analysis to 
understand the underlying reasons shown in these results and policy implications 
will be investigated in the presentation.
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objeCtives: To describe estimated health resource (HR) and criminal justice (CJ) 
system costs for patients with schizophrenia recently released from incarceration 
that are participating in a clinical trial. Methods: Interim baseline HR and CJ events 
collected via a resource use questionnaire from a clinical study of individuals with 
schizophrenia recently released from incarceration were analyzed. HR and CJ utiliza-
tion were evaluated for the most recent CJ event prior to study enrollment, the time 
between this CJ event and enrollment, and the year prior to this CJ event (pre-period). 
HR and CJ cost estimates were obtained from administrative claims and published 
literature then applied to the utilization data pro-rated to 365 days. Costs were sum-
marized descriptively using a state government payer perspective and presented in 
2011 US dollars. Results: Mean total cost (n= 422) in the year prior to enrollment 
was $28,631(SD $20,680; Median $23,445). Mean cost of the qualifying CJ event was 
$14,824 (SD $14,846; Median $10,819). The top 3 most frequent CJ qualifying events 
were parole/probation violation, drug charges, and disorderly conduct/vagrancy/pub-
lic intoxication. Average duration of observation for time periods before and after the 
qualifying CJ event was 243 days (SD 103) and 66 days (SD 72), respectively. Estimated 
mean HR cost in the period prior to CJ qualifying event (pre-period) was $2,485 (SD 
$4,959; Median $929), and mean CJ cost was $6,668 (SD $12,401; Median $0). Among 
those with at least one CJ event in the pre-period (n= 183), average CJ cost was $15,376 
(SD $14,870; Median $11,095). Mean HR cost between the CJ event and enrollment was 
$2,030 (SD $3,452; Median $846). ConClusions: From a state government perspec-
tive, mental health related HR and CJ contacts are costly and are potentially avoidable. 
These data can be used to model HR and CJ costs in a population with schizophrenia.
